Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

Highlight

• Secondary autoimmune and inflammatory diseases (SAIDs) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are rare, with a 5-year incidence of 0.9% but clinically impactful.
• Bone marrow failure, female donor to male recipient sex mismatch, and chronic graft-versus-host disease (cGvHD) significantly increase SAID risk post-transplantation.
• Median onset occurs approximately 14.5 months post-allo-HSCT, with favorable overall survival rates noted at 2 and 5 years after SAID diagnosis.
• Findings underscore the need for enhanced recognition, standardized diagnostic criteria, and tailored management strategies for SAIDs in allo-HSCT survivors.

Study Background

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established curative modality for various hematological malignancies and severe aplastic anemia. Despite advances improving survival, allo-HSCT remains complicated by immune dysregulation, including graft-versus-host disease (GvHD) and infections. Secondary autoimmune and inflammatory diseases (SAIDs) represent less well-characterized immune-mediated complications arising post-transplant. Due to limited data on their epidemiology, pathogenesis, and clinical outcomes, SAIDs are underrecognized and non-standardized in clinical management. Understanding the burden and risk factors of SAIDs after allo-HSCT is crucial to optimizing patient care and developing preventive and therapeutic strategies.

Study Design

This study utilized a retrospective multicenter analysis from the European Society for Blood and Marrow Transplantation (EBMT) database. It included adult and pediatric patients who underwent allo-HSCT between 2005 and 2019 for hematological malignancies or severe aplastic anemia. Cases were defined by the occurrence of secondary autoimmune and inflammatory diseases post-transplant, with 129 patients identified as SAID cases. The control group consisted of 14,617 transplanted patients without documented SAIDs. The primary endpoint was the cumulative incidence of SAIDs at 5 and 10 years post-transplant. Secondary outcomes included survival after SAID diagnosis and identification of associated risk factors using multivariate Cox regression analysis.

Key Findings

The incidence of SAIDs was found to be low but non-negligible: 0.9% (95% CI: 0.7–1.1) at 5 years and 1.1% (95% CI: 0.9–1.3) at 10 years after allo-HSCT. The median latency from transplantation to SAID diagnosis was approximately 442 days (interquartile range 242–1082 days), indicating a late post-transplant event. The overall survival after SAID onset was relatively favorable, with 83.4% survival at 2 years and 73.4% at 5 years, suggesting that despite their immune-mediated nature, these conditions may be manageable with appropriate care.

Multivariate analysis revealed important risk factors independently associated with the development of SAIDs. Patients transplanted for bone marrow failure syndromes exhibited a significantly higher hazard (HR 3.41, 95% CI 1.55–7.52, p=0.002) compared to patients with hematological malignancies. A female donor to male recipient sex mismatch was also associated with increased SAID risk (HR 1.77, 95% CI 1.15–2.73, p=0.009). Moreover, the presence of chronic graft-versus-host disease (cGvHD) increased SAID risk (HR 1.61, 95% CI 1.04–2.51, p=0.034), underscoring the role of donor immune dysregulation and chronic immune activation in secondary autoimmunity.

Expert Commentary

The study robustly highlights that while SAIDs are infrequent post-allo-HSCT, their occurrence is clinically significant and linked to specific transplant-related variables. The association of bone marrow failure with SAID risk may reflect an underlying intrinsic immune dysregulation prior to transplant. The sex mismatch risk is consistent with prior observations that gender mismatches can influence immune alloreactivity, potentially triggering aberrant autoimmune responses. Chronic GvHD, already a known driver of immune pathology, likely contributes to an environment favoring autoimmunity development.

Despite providing valuable epidemiological data, the retrospective design limits assessment of pathophysiological mechanisms and finer-grained clinical phenotyping of SAIDs. Prospective studies with standardized diagnostic criteria and biomarker analyses are warranted. The favorable survival after SAID diagnosis contrasts with other severe allo-HSCT complications, suggesting that with timely diagnosis and management, patients with secondary autoimmunity may achieve good outcomes.

Conclusion

This EBMT registry-based retrospective study clarifies the incidence, timing, and risk factors for secondary autoimmune and inflammatory diseases following allo-HSCT. Although rare, these conditions are an important consideration for transplant clinicians, particularly in patients with bone marrow failure, female-to-male donor-recipient pairs, and chronic GvHD. These findings highlight unmet needs for improving recognition, standardized diagnosis, and development of prevention and treatment protocols. Increasing awareness may lead to better patient management and outcomes in the growing population of allo-HSCT survivors.

Funding and ClinicalTrials.gov

No specific funding was reported for this retrospective analysis. The study utilized EBMT registry data, which reflects multi-institutional contributions across Europe. As a retrospective database study, it was not registered as a clinical trial.

References

1. Mekinian A, Oganesyan A, Perić Z, et al. Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties. Bone marrow transplantation. 2026 Jul 27. PMID: 42509428.
2. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374-384.
3. Arora M, et al. Risk factors and outcomes of autoimmune complications after allogeneic hematopoietic stem cell transplantation. Blood. 2011;118(23):4936-4945.